Evidence map›Paper›PMID 39456169›Full record

ArticleBiomolecules2024

Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis.

Stella Bähr, Ryan W Rue, Carly J Smith, Jillian F Evans, Hubert Köster, Vera P Krymskaya, Dirk Pleimes

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Brazilian Thoracic Association recommendations for the management of lymphangioleiomyomatosis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025
    Guideline
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Stella BährFaculty of Engineering Sciences, Heidelberg University, 69120 Heidelberg, Germany.ORCID 0009-0001-8645-1878
Ryan W RueBiosputnik LLC., New York, NY 10002, USA.ORCID 0009-0004-1608-9780
Carly J SmithBiosputnik LLC., New York, NY 10002, USA.ORCID 0000-0003-3755-6785
Jillian F EvansDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Hubert KösterEmeritus Professor of Organic Chemistry and Biochemistry, University Hamburg, 20148 Hamburg, Germany.
Vera P KrymskayaDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-0584-4486
Dirk PleimesBiosputnik LLC., New York, NY 10002, USA.

Funding

Nitazoxanide as a Novel Therapy for Rare Disease Lymphangioleiomyomatosis and Tuberous SclerosisR41HL156767 · NHLBI · BIOSPUTNIK LLC · PI KRYMSKAYA, VERA P, PLEIMES, DIRK · 2021 to 2021
$256k
National Institutes of Health National Heart, Lung, And Blood Institute 1R41HL156767-01A1NHLBI NIH HHS R41 HL156767
6 · The paper itself

Abstract

Lymphangioleiomyomatosis (LAM) is a rare genetic lung disease. Unfortunately, treatment with the mTORC1 inhibitor Rapamycin only slows disease progression, and incomplete responses are common. Thus, there remains an urgent need to identify new targets for the development of curative LAM treatments. Nitazoxanide (NTZ) is an orally bioavailable antiprotozoal small molecule drug approved for the treatment of diarrhea caused by

Indexed as

Cell ProliferationDrug RepositioningLymphangioleiomyomatosisNitro CompoundsThiazolesAnimalsCell SurvivalFemaleHumansMechanistic Target of Rapamycin Complex 1MiceTuberous Sclerosis Complex 2 ProteinMechanistic Target of Rapamycin Complex 1nitazoxanideNitro CompoundsThiazolesTsc2 protein, mouseTuberous Sclerosis Complex 2 Proteindrug repurposinglung diseaselymphangioleiomyomatosisNitazoxaniderare disease

Identifiers

PMID39456169
PMCPMC11506457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.